Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Synergy Pharma Cmn (SGYP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart


See More
  • Market Capitalization, $K 941,566
  • Shares Outstanding, K 223,120
  • Annual Sales, $ 0 K
  • Annual Income, $ -198,610 K
  • 36-Month Beta 949.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 20.47

Price Performance

See More
Period Period Low Period High Performance
3.98 +3.52%
on 04/06/17
4.84 -14.88%
on 03/29/17
-0.57 (-12.15%)
since 03/28/17
3.98 +3.52%
on 04/06/17
7.15 -42.38%
on 01/31/17
-2.15 (-34.29%)
since 01/27/17
2.62 +57.25%
on 05/12/16
7.15 -42.38%
on 01/31/17
+0.82 (+24.85%)
since 04/28/16

Most Recent Stories

More News
Rasna Therapeutics Names Dr. Kunwar Shailubhai As New CEO

Rasna Therapeutics, Inc. (OTCQX:RASP), is pleased to announce the appointment of Dr. Kunwar Shailubhai as Chief Executive Officer.

RASP : 1.5000 (+76.47%)
SGYP : 4.12 (-2.37%)
Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE(TM) (Plecanatide) Patent Protection Until 2032

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the United States Patent and Trademark Office (USPTO) has issued three new patents covering TRULANCE (plecanatide). The first...

SGYP : 4.12 (-2.37%)
Synergy Pharmaceuticals Launches the Poop Troop, the First Emoji Keyboard Designed to Support Dialogue Around Chronic Idiopathic Constipation (CIC)

Synergy Pharmaceuticals today announced the launch of the Poop Troop, a series of 14 animated emojis designed to encourage conversation and allow people to better express the physical...

SGYP : 4.12 (-2.37%)
Drug Makers Stocks Under Scanner -- Synergy Pharma, Novo Nordisk, Apricus Biosciences, and Sucampo Pharma has issued research reports on four Drug Manufacturers stocks, which are: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), Novo Nordisk A/S (NYSE: NVO), Apricus Biosciences Inc. (NASDAQ:...

SCMP : 10.15 (+0.50%)
NVO : 38.68 (-0.26%)
APRI : 1.13 (+1.80%)
SGYP : 4.12 (-2.37%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

SGYP : 4.12 (-2.37%)
Synergy Pharmaceuticals Submits Supplemental New Drug Application (sNDA) for TRULANCE(TM) (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the company has submitted a supplemental New Drug Application (sNDA) for TRULANCE(TM) (plecanatide) for the treatment of adults...

SGYP : 4.12 (-2.37%)
Synergy Pharmaceuticals Enters Oversold Territory (SGYP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

SGYP : 4.12 (-2.37%)
Interesting SGYP Put And Call Options For May 19th

Investors in Synergy Pharmaceuticals Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options...

SGYP : 4.12 (-2.37%)
CORRECTING and REPLACING Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update

Please replace the release, dated March 1, 2017, with the following corrected version due to multiple revisions in the Financial Results bullets and financial tables.

SGYP : 4.12 (-2.37%)
Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial...

SGYP : 4.12 (-2.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant-...

See More

Support & Resistance

2nd Resistance Point 4.27
1st Resistance Point 4.20
Last Price 4.12
1st Support Level 4.08
2nd Support Level 4.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.